As the second half of 2024 begins, VEMINSYN has celebrated two major milestones.
Type XVII Collagen Peptide, independently developed and manufactured by VEMINSYN’s R&D team, has been successfully registered with an INCI name and included in the International Cosmetic Ingredient Dictionary and Handbook by PCPC, making it the first Type XVII Collagen Peptide ingredient ever recognized by PCPC.
In the meantime, VEMINSYN has also been granted an invention patent for Type XVII Collagen Peptide(Patent Title: Recombinant Type XVII Collagen for Skin Anti-Aging, Preparation Method and Application Thereof; Patent No.: 202211621908.5).
These two key achievements not only consolidate VEMINSYN’s leading position in the domestic beauty raw material industry, but also mark an important step forward for the company into the global market.
Small Molecular Collagen —— Type XVII Collagen
Type XVII Collagen (Col17a1) is distinct from conventional fibroblast collagen. As a transmembrane collagen, it serves as a signaling molecule that regulates cells, maintains intercellular homeostasis and the rhythm of cellular self-purification, and clears senescent cells. It is therefore essential for preserving youthful and healthy skin.
With aging, as well as UV damage, stress and other external factors, Type XVII Collagen in the human body gradually degrades and diminishes. This suppresses related signaling pathways, weakens the cellular self-purification mechanism, and accelerates skin aging.
In the personal care and skincare industry, effective supplementation of Type XVII Collagen relies on low-molecular-weight Type XVII Collagen Peptide that can penetrate and be absorbed by the skin.
VEMINSYN’s low-molecular-weight Type XVII Collagen Peptide rapidly reaches the epidermal-dermal junction — the functional depth where Type XVII Collagen Peptide exerts its effects — within just 2 hours, achieving genuine deep penetration into the epidermis.
For reference:
Commercially available Type XVII Collagen (2–5 kDa) fails to penetrate the stratum corneum within 4 hours.
Type XVII Collagen (20–25 kDa) remains on the surface of the stratum corneum even after 4 hours.
About Type XVII Collagen Peptide
1. Time‑Col17
Time‑Col17 is the active core screened from more than 1.3 million amino‑acid sequences of human Type XVII collagen.With a molecular weight below 1000 Da, it can penetrate deep into the skin base. Acting as a signaling protein mimic, it performs the same key functions as native Type XVII collagen: maintaining intercellular homeostasis, clearing senescent cells, and activating fibroblasts through feedback loops.
It further boosts the production of multiple types of collagen, increases collagen density, and preserves a youthful and healthy skin condition, that retains the critical functions of the full‑size macromolecule within a small molecular unit.
2. Hair‑Col17
With advancing age, the progressive loss of Type XVII Collagen leads to natural atrophy of hair follicles, ultimately resulting in hair loss.
Hair‑Col17, developed by the VEMINSYN team, is a scalp‑care collagen designed as an anti‑hair loss and hair‑strengthening product based on Type XVII Collagen.It effectively reduces senescent cells in hair follicles and regulates sebum production, thereby visibly delaying the progression of hair loss.
3. Petite‑Col17
As a soothing small‑molecule Type XVII collagen,Petite‑Col17 is an anti‑aging ingredient suitable for sensitive skin.
It inhibits multiple inflammatory factors, efficiently promotes the synthesis of DEJ‑related proteins, and maintains skin stability and health.With additional soothing and anti-irritation benefits, it reduces redness‑prone areas and effectively improves facial redness and related skin concerns.
Obtaining an INCI name is undoubtedly a significant recognition of VEMINSYN’s R&D team and has further paved the way for the company to enter the international market. The grant of the invention patent for Type XVII Collagen Peptide has provided additional motivation to the team.
Moving forward, VEMINSYN will continue to uphold its mission of dedicating to the innovation and R&D of biomaterials. The company will keep optimizing its product portfolio, driving technological innovation, and providing safer and more effective skincare raw materials for consumers around the world.
VEMINSYN firmly believes that more good news will come in the future, injecting new momentum into the company’s development and creating a better living experience for consumers.
